Literature DB >> 21502956

Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry.

S Lehmann1, A Ravn, L Carlsson, P Antunovic, S Deneberg, L Möllgård, A Rangert Derolf, D Stockelberg, U Tidefelt, A Wahlin, L Wennström, M Höglund, G Juliusson.   

Abstract

Our knowledge about acute promyelocytic leukemia (APL) patients is mainly based on data from clinical trials, whereas population-based information is scarce. We studied APL patients diagnosed between 1997 and 2006 in the population-based Swedish Adult Acute Leukemia Registry. Of a total of 3897 acute leukemia cases, 3205 (82%) had non-APL acute myeloid leukemia (AML) and 105 (2.7%) had APL. The incidence of APL was 0.145 per 100,000 inhabitants per year. The median age at the time of diagnosis was 54 years; 62% were female and 38% male. Among younger APL patients, female sex predominated (89% of patients <40 years). Of the 105 APL patients, 30 (29%) died within 30 days (that is, early death (ED)) (median 4 days) and 28 (26%) within 14 days from diagnosis. In all, 41% of the EDs were due to hemorrhage; 35% of ED patients never received all-trans-retinoic acid treatment. ED rates increased with age but more clearly with poor performance status. ED was also associated with high white blood cells, lactate dehydrogenase, creatinine, C-reactive protein and low platelet count. Of non-ED patients, 97% achieved complete remission of which 16% subsequently relapsed. In total, 62% are still alive at 6.4 years median follow-up. We conclude that ED rates remain very high in an unselected APL population.

Entities:  

Mesh:

Year:  2011        PMID: 21502956     DOI: 10.1038/leu.2011.78

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  85 in total

1.  Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era.

Authors:  Simon Mantha; Debra A Goldman; Sean M Devlin; Ju-Whei Lee; Diana Zannino; Marnie Collins; Dan Douer; Harry J Iland; Mark R Litzow; Eytan M Stein; Frederick R Appelbaum; Richard A Larson; Richard Stone; Bayard L Powell; Susan Geyer; Kristina Laumann; Jacob M Rowe; Harry Erba; Steven Coutre; Megan Othus; Jae H Park; Peter H Wiernik; Martin S Tallman
Journal:  Blood       Date:  2017-01-12       Impact factor: 22.113

2.  Reducing mortality in newly diagnosed standard-risk acute promyelocytic leukemia in elderly patients treated with arsenic trioxide requires major reduction of chemotherapy: a report by the French Belgian Swiss APL group (APL 2006 trial).

Authors:  Ramy Rahmé; Lionel Ades; Xavier Thomas; Agnès Guerci-Bresler; Arnaud Pigneux; Norbert Vey; Emmanuel Raffoux; Sylvie Castaigne; Olivier Spertini; Sebastian Wittnebel; Jean Pierre Marolleau; Gandhi Damaj; Dominique Bordessoule; Julie Lejeune; Sylvie Chevret; Pierre Fenaux
Journal:  Haematologica       Date:  2018-05-24       Impact factor: 9.941

3.  Clinical impact of FLT3 mutation load in acute promyelocytic leukemia with t(15;17)/PML-RARA.

Authors:  Susanne Schnittger; Ulrike Bacher; Claudia Haferlach; Wolfgang Kern; Tamara Alpermann; Torsten Haferlach
Journal:  Haematologica       Date:  2011-08-22       Impact factor: 9.941

4.  Corpus Callosum Bleed: A Rare Presentation of Acute Promyelocytic Leukemia.

Authors:  Aditya Jandial; Kundan Mishra; Mithun Sekhar; Rajeev Sandal; Deepesh Lad; Gaurav Prakash; Alka Khadwal; Jasmina Ahluwalia; Pankaj Malhotra
Journal:  Indian J Hematol Blood Transfus       Date:  2018-11-12       Impact factor: 0.900

5.  Early death rates remain high in high-risk APL: update from the Swedish Acute Leukemia Registry 1997-2013.

Authors:  S Lehmann; S Deneberg; P Antunovic; Å Rangert-Derolf; H Garelius; V Lazarevic; K Myhr-Eriksson; L Möllgård; B Uggla; A Wahlin; L Wennström; M Höglund; G Juliusson
Journal:  Leukemia       Date:  2017-02-24       Impact factor: 11.528

Review 6.  Pathogenesis of disseminated intravascular coagulation in patients with acute promyelocytic leukemia, and its treatment using recombinant human soluble thrombomodulin.

Authors:  Takayuki Ikezoe
Journal:  Int J Hematol       Date:  2013-11-12       Impact factor: 2.490

7.  Influence of initiation time and white blood cell count on the efficacy of cytotoxic agents in acute promyelocytic leukemia during induction treatment.

Authors:  Fang Xu; Chang-Xin Yin; Chun-Li Wang; Bing-Jie Ding; Qing-Xiu Zhong; Xue-Jie Jiang; Ling Jiang; Zhi-Xiang Wang; Fan-Yi Meng
Journal:  Biomed Rep       Date:  2018-07-02

8.  The results of the International Consortium on Acute Promyelocytic Leukemia: a 'proof of concept' of networking as a strategy to improve the outcome of treatment of hematological malignancies in developing countries.

Authors:  Eduardo Magalhães Rego
Journal:  Rev Bras Hematol Hemoter       Date:  2013

Review 9.  Progress in the treatment of acute promyelocytic leukemia: optimization and obstruction.

Authors:  Junmin Li; Hongming Zhu; Jiong Hu; Jianqing Mi; Saijuan Chen; Zhu Chen; Zhenyi Wang
Journal:  Int J Hematol       Date:  2014-06-18       Impact factor: 2.490

10.  New onset acute promyelocytic Leukemia during pregnancy: report of 2 cases.

Authors:  Huiyang Li; Cha Han; Ke Li; Jie Li; Yingmei Wang; Fengxia Xue
Journal:  Cancer Biol Ther       Date:  2018-11-19       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.